Sung Ji Nam
Stock Analyst at Scotiabank
(2.09)
# 2,850
Out of 4,884 analysts
78
Total ratings
41.54%
Success rate
-5.79%
Average return
Main Sectors:
Stocks Rated by Sung Ji Nam
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
CSTL Castle Biosciences | Maintains: Sector Outperform | $44 → $40 | $20.30 | +97.04% | 6 | May 21, 2025 | |
BDSX Biodesix | Maintains: Sector Outperform | $3 → $2 | $0.27 | +636.38% | 2 | May 21, 2025 | |
MYGN Myriad Genetics | Downgrades: Sector Perform | $20 → $6 | $5.60 | +7.14% | 4 | May 21, 2025 | |
GH Guardant Health | Maintains: Sector Outperform | $52 → $57 | $50.50 | +12.87% | 5 | May 5, 2025 | |
TMO Thermo Fisher Scientific | Maintains: Sector Perform | $650 → $605 | $429.33 | +40.92% | 14 | Apr 25, 2025 | |
BNGO Bionano Genomics | Maintains: Sector Perform | $1 → $4 | $3.37 | +18.69% | 6 | Apr 2, 2025 | |
PACB Pacific Biosciences of California | Maintains: Sector Outperform | $6 → $2 | $1.60 | +25.00% | 5 | Mar 25, 2025 | |
EXAS Exact Sciences | Maintains: Sector Outperform | $70 → $73 | $53.36 | +36.81% | 2 | Feb 24, 2025 | |
ADPT Adaptive Biotechnologies | Maintains: Sector Outperform | $10 → $12 | $11.80 | +1.69% | 2 | Feb 13, 2025 | |
WAT Waters | Upgrades: Sector Outperform | $430 → $450 | $350.22 | +28.49% | 2 | Feb 13, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $88 → $90 | $53.14 | +69.36% | 2 | Feb 6, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $54 → $62 | $38.17 | +62.43% | 5 | Feb 4, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Perform | $265 | $203.20 | +30.41% | 1 | Dec 23, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $40 → $44 | $27.51 | +59.94% | 4 | Nov 8, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $35 | $19.24 | +81.91% | 4 | Nov 5, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $176 → $164 | $100.80 | +62.70% | 9 | Aug 15, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $6 | $5.21 | +15.16% | 2 | Jun 29, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $20.06 | - | 3 | Nov 24, 2020 |
Castle Biosciences
May 21, 2025
Maintains: Sector Outperform
Price Target: $44 → $40
Current: $20.30
Upside: +97.04%
Biodesix
May 21, 2025
Maintains: Sector Outperform
Price Target: $3 → $2
Current: $0.27
Upside: +636.38%
Myriad Genetics
May 21, 2025
Downgrades: Sector Perform
Price Target: $20 → $6
Current: $5.60
Upside: +7.14%
Guardant Health
May 5, 2025
Maintains: Sector Outperform
Price Target: $52 → $57
Current: $50.50
Upside: +12.87%
Thermo Fisher Scientific
Apr 25, 2025
Maintains: Sector Perform
Price Target: $650 → $605
Current: $429.33
Upside: +40.92%
Bionano Genomics
Apr 2, 2025
Maintains: Sector Perform
Price Target: $1 → $4
Current: $3.37
Upside: +18.69%
Pacific Biosciences of California
Mar 25, 2025
Maintains: Sector Outperform
Price Target: $6 → $2
Current: $1.60
Upside: +25.00%
Exact Sciences
Feb 24, 2025
Maintains: Sector Outperform
Price Target: $70 → $73
Current: $53.36
Upside: +36.81%
Adaptive Biotechnologies
Feb 13, 2025
Maintains: Sector Outperform
Price Target: $10 → $12
Current: $11.80
Upside: +1.69%
Waters
Feb 13, 2025
Upgrades: Sector Outperform
Price Target: $430 → $450
Current: $350.22
Upside: +28.49%
Feb 6, 2025
Maintains: Sector Outperform
Price Target: $88 → $90
Current: $53.14
Upside: +69.36%
Feb 4, 2025
Maintains: Sector Outperform
Price Target: $54 → $62
Current: $38.17
Upside: +62.43%
Dec 23, 2024
Initiates: Sector Perform
Price Target: $265
Current: $203.20
Upside: +30.41%
Nov 8, 2024
Maintains: Sector Outperform
Price Target: $40 → $44
Current: $27.51
Upside: +59.94%
Nov 5, 2024
Maintains: Buy
Price Target: $40 → $35
Current: $19.24
Upside: +81.91%
Aug 15, 2024
Maintains: Sector Outperform
Price Target: $176 → $164
Current: $100.80
Upside: +62.70%
Jun 29, 2023
Assumes: Buy
Price Target: $6
Current: $5.21
Upside: +15.16%
Nov 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $20.06
Upside: -